


# *Predictive value of Serum CA125 In Patients with Ovarian Masses*

Thesis

Submitted for Partial Fulfillment of M.D. Degree  
*In Obstetrics and Gynaecology*



6/8-11  
A-H

Presented by

AMR<sup>o</sup> HASSAN EL-SHALAKANY

52920

Under Supervision of

**PROF. DR. EL-SAYED EL-MAHGOUB**

*Professor of Obstetrics and Gynaecology  
Ain Shams University*

**PROF. DR. ALI KHALIFA**

*Professor of Biochemistry  
Ain Shams University*

**PROF. DR. MOHAMED MEHANNA**

*Professor of Obstetrics and Gynaecology  
Ain Shams University*

**DR. AHMED SALAH KAMEL**

*Lecturer of Pathology  
Ain Shams University*

**FACULTY OF MEDICINE**

**AIN SHAMS UNIVERSITY**



**1992**

**This work is dedicated to**

***My Wife***



## ACKNOWLEDGEMENT

I would like to express my gratitude and esteem to Professor DR. EL-SAYED EL-MAHGOUB and Professor DR. MOHAMED MEHANNA, Department of Obstetrics and gynaecology, Faculty of Medicine, Ain Shams University and Professor DR. ALI KHALIFA, Department of Biochemistry, Faculty of Medicine, Ain Shams University. Not only they guided the choice of the subject and laid out the work plan but also they continually gave their productive advice and sincere encouragement. Thanks to their efforts, this thesis came to a conclusion.

I also would like to thank DR. AHMED SALAH, lecturer of Pathology, Faculty of Medicine, Ain Shams University who supervised the interpretation of all pathology specimens and helped to put the layout of this thesis.

Lastly, I would like to thank DR. MOSTAFA EL-RASAD, Assistant Professor of Biochemistry, and Professor DR. OMAR EL-AHMADY, Al Azhar University who performed the immunoradiometric assays. They were also involved in the the interpretation and the processing of results.

## CONTENTS

■ INTRODUCTION .....	1
■ AIM OF THE WORK .....	2
■ REVIEW OF THE LITERATURE .....	3
• Ovarian Tumours .....	3
◦ Classification .....	3
◦ Malignant ovarian neoplasia .....	7
◦ Staging .....	9
◦ Management of ovarian cancer .....	12
• Tumour Antigens ..... Historical Review .....	16
• Tumour Markers .....	22
◦ Definition .....	22
◦ Classification .....	23
◦ Clinical application of tumour markers .....	24
• Cancer Antigen 125 (CA 125) .....	29
◦ Chemistry of CA 125 .....	30
◦ Detection of CA 125 in tissues and serum .....	31
◦ Distribution of CA125 .....	32
◦ CA 125 in pregnancy .....	32
◦ CA 125 levels during the menstrual cycle .....	35
• CA 125 in Gynaecologic Practice .....	38
◦ CA 125 in patients with endometriosis .....	38
◦ Role of CA 125 in screening for ovarian cancer .....	43
◦ Clinical significance of preoperative serum CA 125 in ovarian tumours .....	46
◦ Role of CA 125 in monitoring patients with ovarian cancer .....	52
◦ Role of serum CA 125 in other gynaecologic malignancies .....	61
■ MATERIAL AND METHODS .....	65
■ RESULTS .....	69
■ DISCUSSION .....	90
■ CONCLUSION .....	94
■ SUMMARY .....	95
■ REFERENCES .....	98
■ ARABIC SUMMARY	

## LIST OF FIGURES

Figure (1):	Hybridoma technique for production of monoclonal antibodies .....	78
Figure (2):	Preoperative CA 125 levels in the 4 groups of patients .....	75
Figure (3):	Showing serum CA 125 pre- and postoperatively in patients with malignant disease who had remission .....	86
Figure (4):	Showing serum CA 125 pre- and postoperatively in patients who had progressive malignant disease .....	87
Figure (5):	Showing serum CA 125 pre- and postoperatively in patients with endometriosis .....	89

## LIST OF TABLES

Table (A):	Clinical findings and serum CA 125 levels pre- and postoperatively in patients with malignant ovarian neoplasia (Group I). .....	71
Table (B):	Clinical findings and serum CA 125 levels pre- and postoperatively in patients with benign ovarian neoplasia (Group II) .....	72
Table (C):	Clinical findings and serum CA 125 levels pre- and postoperatively in patients with endometriosis and other tumour-like masses (group III and IV) .....	73
Table (1):	A guide for tumour markers .....	25
Table (2):	Serum CA 125 levels in the control group .....	74
Table (3):	Showing distribution of normal and abnormal CA 125 levels at the cut-off level of 35 U/ml and 65 U/ml .....	76
Table (4):	Showing the characteristics of preoperative CA 125 assay at cut-off levels 35 U/ml and 65 U/ml .....	76
Table (5):	Showing distribution of preoperative suspicions of malignancy from clinical and sonographic assessment in various pathologic groups .....	77
Table (6a):	Comparing the diagnostic values of preoperative CA 125 and clinical and sonographic impression .....	78
Table (6b):	Comparing serum CA 125 and clinical and ultrasound examination suspicion malignancy to predict it in group (I) .....	79
Table (7):	Comparing preoperative CA 125 serum levels in patients with and without ascites .....	80
Table (8):	Comparing preoperative serum CA 125 in patients with and without positive cytology .....	80
Table (9):	Showing diagnostic value of CA 125 in pre- and postmenopausal patients .....	81
Table (10):	Showing distribution of positive serum CA 125 levels preoperatively in different FIGO stages .....	83
Table (11):	Comparing preoperatively serum CA 125 values in patients who had remission and those with progressive malignant disease .....	83
Table (12):	Showing patients attendance to the follow up visits .....	84
Table (13):	Comparing 1st week postoperative serum CA 125 levels in patients in remission and those with progressive malignant disease .....	85



# *Introduction & Aim of the Work*



## INTRODUCTION

Ovarian cancer accounts for more deaths than cancer of the uterine cervix and corpus (*Hudson, 1985*). Indeed, 70% of patients have metastases beyond the pelvis at the time of diagnosis (*Piver, 1983*). The 5-year survival rate is about 20% in advanced disease (stage III and IV) compared with almost 80% in patients with stage I disease (The overall 5-year survival rate has not changed over the past 20 year and remains at approximately 25-30% (*Piver, 1989*).

This poor survival is mainly attributable to late diagnosis due to the insidious nature of the disease, to the unreliability of clinical examination and to the lack of an effective early screening technique (*DiSaia and Creasman, 1989*).

The existence of effective therapy nowadays accentuates the need for a sensitive tumour marker in this concealed disease. The value of tumour markers has already been established in gynaecological oncology. In ovarian germ cell tumours and gestational choriocarcinoma, estimation of alpha fetoprotein (AFP), human chorionic gonadotrophin hCG and Schwangerschaft's protein 1 (SPI) provide a quantitative assessment of viable tumour load (*Bagshawe, 1976*).

In the context of epithelial ovarian cancer several potential markers have been investigated (*Sepala et al., 1975; Knauf and Urbach, 1978*). Of these, the antigenic determinant CA 125 appears to be the most useful clinically with a reported sensitivity of 82% and a concordance with disease states of 93% (*Bast et al., 1983; Dodd et al., 1985*). CA 125 was first defined by *Bast et al. in 1981* by a murine IgG1 monoclonal antibody raised against the serous ovarian carcinoma cell line OVCA 433 (*Bast et al., 1981*).

## AIM OF THE WORK

Evaluation of the significance of serum CA 125 levels in diagnosis, management and follow up of patients with ovarian masses.



# *Review of Literature*



# OVARIAN TUMOURS

Neoplasms of the ovary present an increasing challenge to the physician. They are the cause of more deaths than any other female genital tract cancer.

The gynecologic oncologist is frustrated by the limitation of knowledge available about etiologic factors in ovarian cancer and by the failure to achieve a significant reduction in mortality from these neoplasms over the past six decades (*DiSaia and Creasman, 1989*).

## CLASSIFICATION

The student of ovarian pathology is often confused by the enormous variation in histologic structure and biologic behaviour. For the purpose of standardization for comparing results in different centres, the World Health Organization (WHO) adopted a pathological classification in 1973. The WHO classification is based on the histological cell of origin and no account is taken of the gross characteristics or functional activity of the tumour.

The WHO classification of ovarian tumours is as follows:

### I. Common "epithelial" tumours

#### A. *Serous Tumours*

##### 1. Benign

- a. Cystadenoma and papillary cystadenoma.
- b. Surface papilloma.
- c. Adenofibroma and cystadenofibroma.

## 2. Of borderline malignancy (of low malignant potential)

- a. Cystadenoma and papillary cystadenoma.
- b. Surface papilloma.
- c. Adenofibroma and cystadenofibroma.

## 3. Malignant

- a. Adenocarcinoma, papillary adenocarcinoma and papillary cystadenocarcinoma.
- b. Surface papillary carcinoma.
- c. Malignant adenofibroma and cystadenofibroma.

### *B. Mucinous tumours*

#### 1. Benign

- a. cystadenoma
- b. adenofibroma and cystadenofibroma.

#### 2. Of border line malignancy (of low malignant potential)

- a. cystadenoma.
- b. adenofibroma and cystadenofibroma.

#### 3. Malignant

- a. Adenocarcinoma and cystadenocarcinoma.
- b. Malignant adenofibroma and cystadenofibroma.

### *C. Endometrioid tumours*

#### 1. Benign

- a. Adenoma and cystadenoma.
- b. Adenofibroma and cystadenofibroma.

#### 2. Of border line malignancy (of low malignant potential)

- a. Adenoma and cystadenoma.
- b. Adenofibroma and cystadenofibroma.

#### 3. Malignant

- a. Carcinoma
  - 1. Adenocarcinoma

2. Adenoacanthoma
3. Malignant adenofibroma and cystadenofibroma.
- b. Endometrioid stromal sarcomas.
- c. Mesodermal (mullerian) mixed tumours, homologous and heterologous.

*D. Clear cell (mesonephroid) tumours*

1. Benign: adenofibroma.
2. Of borderline malignancy ( of low malignant potential).
3. Malignant: carcinoma and adenocarcinoma.

*E. Brenner tumours*

1. Benign
2. Of borderline malignancy (proliferating).
3. Malignant

*F. Mixed epithelial tumours*

1. Benign
2. Of borderline malignancy.
3. Malignant

*G. Undifferentiated carcinoma*

*H. Unclassified epithelial tumours.*

*II. Sex cord stromal tumours*

**A. Granulosa-Stromal Cell Tumours**

1. Granulosa cell tumour
2. Thecoma-fibroma group of tumours.
  - a. Thecoma
  - b. Fibroma
  - c. Unclassified.

## B. Androblastomas: Sertoli-Leydig cell tumours

1. Well differentiated
  - a. Tubular androblastomas: Sertoli-cell tumour (tubular adenoma of Pick).
  - b. Tubular androblastoma with lipid storage (Sertoli-cell tumour with lipid-storage) (folliculome lipidique of Lecene).
  - c. Sertoli-Leydig cell tumour (tubular adenoma with Leydig cells).
  - d. Leydig cell tumour (hilus cell tumour).
2. Of intermediate differentiation.
3. Poorly differentiated (sarcomatoid).
4. With heterogenous elements.

## C) Gynandroblastoma.

## D) Unclassified.

### *III. Lipid cell tumours*

### *IV. Germ Cell tumours*

- A. Dysgerminoma.
- B. Endodermal sinus tumour.
- C. Embryonal carcinoma.
- D. Polyembryoma.
- E. Choriocarcinoma.
- F. Teratomas.
  1. Immature
  2. Mature
    - a. solid
    - b. cystic
      1. Dermoid cyst (mature cystic teratoma).
      2. Dermoid cyst with malignant transformation.